Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (<scp>WBMT</scp>)

Autologous hematopoietic cell transplantation (AHCT) is a commonly used treatment in multiple myeloma (MM). However, real-world global demographic and outcome data are scarce. We collected data on baseline characteristics and outcomes from 61 725 patients with newly diagnosed MM who underwent upfront AHCT between 2013 and 2017 from nine national/international registries. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), relapse incidence (RI) and non-relapse mortality (NRM). Median OS amounted to 90.2 months (95% CI 88.2-93.6) and median PFS 36.5 months (95% CI 36.1-37.0). At 24 months, cumulative RI was 33% (95% CI 32.5%-33.4%) and NRM was 2.5% (95% CI 2.3%-2.6%). In the multivariate analysis, superior outcomes were associated with younger age, IgG subtype, complete hematological response at auto-HCT, Karnofsky score of 100%, international staging scoring (ISS) stage 1, HCT-comorbidity index (CI) 0, standard cytogenetic risk, auto-HCT in recent years, and use of lenalidomide maintenance. There were differences in the baseline characteristics and outcomes between registries. While the NRM was 1%-3% at 12 months worldwide, the OS at 36 months was 69%-84%, RI at 12 months was 12%-24% and PFS at 36 months was 43%-63%. The variability in these outcomes is attributable to differences in patient and disease characteristics as well as the use of maintenance and macroeconomic factors. In conclusion, worldwide data indicate that AHCT in MM is a safe and effective therapy with an NRM of 1%-3% with considerable regional differences in OS, PFS, RI, and patient characteristics. Maintenance treatment post-AHCT had a beneficial effect on OS.

Authors

Institutions

Publication Details

Journal
American Journal of Hematology
Published
2024-08-19
DOI
https://doi.org/10.1002/ajh.27451
Citations
9
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
4.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT)

Minako Iida, Arleigh McCurdy, Laurien Baaij, S. Keat Tan et al.
9 citations
American Journal of Hematology
Multiple Myeloma Research and Treatments
4.09
article

Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT)

Minako Iida, Arleigh McCurdy, Laurien Baaij, S. Keat Tan, Christopher Liam, Qamar Un Nisa Chaudhry, Donal P. McLornan, Rozan Alfar, Noel Estrada‐Merly, A. Sim Goh, John A. Snowden, Laurent Garderet, Feng Rong Wang, Parameswaran Hari, Yoshihisa Kodera, Ali Bazarbachi, Mickey Koh, Hiroyuki Takamatsu, Anita D’Souza, Dietger Niederwieser, Alaa Elhaddad, Shinichiro Okamoto, Shohei Mizuno, Stefan Schönland, Hira S. Mian, Wael Saber, Francisca Bass, Malek Benakli, Sebastián Galeano, Anna Sureda, Luuk Gras, Eloísa Riva, Nada Hamad, Bor‐Sheng Ko, Mahmoud Aljurf, Daniel Neumann, Cristobal Augusto Frutos Ortiz, Kim Wah Ho, Andrew J. Cowan, Koji Kawamura, Patrick Hayden, Hildegard Greinix, Linda Köster, Mohamed‐Amine Bekadja, Ly Meng, Yoshiko Atsuta
article en
9 citations

Abstract

Autologous hematopoietic cell transplantation (AHCT) is a commonly used treatment in multiple myeloma (MM). However, real-world global demographic and outcome data are scarce. We collected data on baseline characteristics and outcomes from 61 725 patients with newly diagnosed MM who underwent upfront AHCT between 2013 and 2017 from nine national/international registries. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), relapse incidence (RI) and non-relapse mortality (NRM). Median OS amounted to 90.2 months (95% CI 88.2-93.6) and median PFS 36.5 months (95% CI 36.1-37.0). At 24 months, cumulative RI was 33% (95% CI 32.5%-33.4%) and NRM was 2.5% (95% CI 2.3%-2.6%). In the multivariate analysis, superior outcomes were associated with younger age, IgG subtype, complete hematological response at auto-HCT, Karnofsky score of 100%, international staging scoring (ISS) stage 1, HCT-comorbidity index (CI) 0, standard cytogenetic risk, auto-HCT in recent years, and use of lenalidomide maintenance. There were differences in the baseline characteristics and outcomes between registries. While the NRM was 1%-3% at 12 months worldwide, the OS at 36 months was 69%-84%, RI at 12 months was 12%-24% and PFS at 36 months was 43%-63%. The variability in these outcomes is attributable to differences in patient and disease characteristics as well as the use of maintenance and macroeconomic factors. In conclusion, worldwide data indicate that AHCT in MM is a safe and effective therapy with an NRM of 1%-3% with considerable regional differences in OS, PFS, RI, and patient characteristics. Maintenance treatment post-AHCT had a beneficial effect on OS.

American Journal of HematologyVol. 99(11)
Kanazawa University (JP), Hospital Británico (UY), Université Oran 1 Ahmed Ben Bella (DZ), Cairo University (EG), Jichi Medical University (JP), Aichi Medical University (JP), St George's, University of London (GB), Medical University of Graz (AT), Peking University (CN), Keio University (JP), Medical College of Wisconsin (US), Trinity College Dublin (IE), Heidelberg University (DE), King Hussein Cancer Center (JO), Ottawa Hospital (CA), King Faisal Specialist Hospital & Research Centre (SA), University Hospital Heidelberg (DE), Penang Adventist Hospital (MY), UNSW Sydney (AU), Sorbonne Université (FR), Institut d'Investigació Biomédica de Bellvitge (ES), St Vincent's Hospital Sydney (AU), Fred Hutch Cancer Center (US), Assistance Publique – Hôpitaux de Paris (FR), Hospital del Salvador (CL), European Society for Blood and Marrow Transplantation (NL), Sheffield Teaching Hospitals NHS Foundation Trust (GB), American University of Beirut Medical Center (LB), Institut Català d'Oncologia (ES), St Vincent's Clinic (AU), National Taiwan University Hospital (TW), Centre de Recherche Nucléaire d’Alger (DZ), Duran i Reynals Hospital (ES), King's College Hospital (GB), St. James's Hospital (IE), Hospital de Clínicas (UY), The Japanese Data Center for Hematopoietic Cell Transplantation (JP), KPJ Ampang Puteri Specialist Hospital (MY), Children Cancer Hospital (EG), Jichi Medical University Saitama Medical Center (JP), IPS Central (PY), Universitat de Barcelona (ES), Leipzig University (DE), The University of Notre Dame Australia (AU), McMaster University (CA)
Amgen, Pfizer, Sanofi, Gilead Sciences, Celgene, Hamilton Health Sciences, Prothena, JCR Pharmaceuticals, Medac
Good health and well-being
Openalex Percentile: Top 6%
Multiple Myeloma Research and Treatments
4.09
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.